Company intelligence / Profile preview
Redwood Scientific Technologies
- Ownership
- Private
- Employees
- ~5
- Development stage
- Commercial
Overview
Redwood Scientific Technologies develops over-the-counter FDA registered drugs using proprietary oral thin film strip technology. The company’s current focus is on nicotine replacement therapy with two lead programs—TBX-FREE™ for smoking cessation and TBX VAPE-FREE™ targeting vape/e-cigarette users. Both are progressing toward clinical validation, with conditional IRB approval received in late 2023. The company aims to be first-to-market with a nicotine-free solution for vape addiction.
- Therapeutic areas
- Psychiatry
- Modalities
- Oral thin film strip (Device/Drug delivery system)Small molecule (for active ingredients in OTC drugs)Nicotine replacement therapy (NRT) products (Drug-device combination)
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Redwood Scientific Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Redwood Scientific Technologies.